Section Review Cardiovascular & Renal: Phosphodiesterase 5 inhibitors in development for cardiovascular therapy

References

• APPLEMAN MM, TERASAKI WL: Regulation of cyclic nu- cleotide phosphodiesterases. Adv. Cyclic Nucleotide Res. (1975) 5:153–162.
   PubMedGoogle Scholar
• BEAVO JA, CONTI M, HEASLIP RJ: Multiple cyclic nucleo-tide phosphodiesterases. Mol. Pharmacol. (1994) 46:399–405.
   PubMed Web of Science ®Google Scholar
• BEAVO JA: Cyclic nucleotide phosphodiesterases: func-tional implications of multiple isoforms. Physiol. Rev. (1995) 75:725–748.
   PubMed Web of Science ®Google Scholar
• BEAVO JA, REIFSNYDER DH: Primary sequence of cyclic •nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. (1990) 11:150–155.
   PubMed Web of Science ®Google Scholar
• WEISHAAR RE, CAIN MH, BRISTOL JA: A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J. Med. Chem. (1985) 28:537–545.
   PubMed Web of Science ®Google Scholar
• BEAVO JA, REIFSNYDER DH: Primary sequence of cyclic ••nudeotide phosphodiesterase isozymes and the designof selective inhibitors. Trends Pharmacol. Sci. (1990) 11:150–155.
   PubMed Web of Science ®Google Scholar
• NICHOLSON CD, CHALLIS RAJ, SHAHID M: Differential •modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodi-esterase isozymes. Trends Pharmacol. Sci. (1991) 12:19–27.
   PubMed Web of Science ®Google Scholar
• PAGANI ED, BUCHHOLZ RA, SILVER PJ: Cardiovascular •cyclic nudeotide phosphodiesterases and their role in regulating cardiovascular function. Basic Res. Cardiol. (1992) 87\(Suppl. 1):73–86. •• •• 15. ••
   Google Scholar
• STOCLET JC, KERAVIS T, KOMAS N, LUGNIER C: Cyclic •nucleotide phosphodiesterases as therapeutic targets In cardiovascular diseases. Exp. Opin. Invest. Drugs (1995) 4(11):1081–1100.
   Google Scholar
• CONTI M, NEMOZ G, SE I It, C, VICINI E: Recent progress ••in understanding the hormonal regulation of phos-phodiesterases. Endocrine Rev. (1995) 16:370–389.
   PubMed Web of Science ®Google Scholar
• POLSON JB, STRADA SJ: Cyclic nucleotide phosphodi-esterases and vascular smooth muscle. Ann. Rev. Phar-macol. Taxicol. (1996) 36:403–427.
   PubMed Web of Science ®Google Scholar
• FRANCIS SH, THOMAS MK, CORBIN JD: Cyclic GMP-bind- •ing cyclic GMP-specific phosphodiesterase from lung. In: Cyclic Nucleotide Phosphodiesterases: Structure, Regula-tion and Drug Action. Beavo JA, Houslay MD (Eds.), John Wiley & Sons Ltd., New York (1990):117–140.
   Google Scholar
• THOMAS MK, FRANCIS SH, CORBIN JD: Characterization of a purified bovine lung cGMP-binding cGMP phos-phodiesterase. J. Biol. Chem. (1990) 265:14964–14970.
   PubMed Web of Science ®Google Scholar
• MCALLISTER-LUCAS LM, SONNENBURG WK, KADLECEK A •et al.: The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J. Biol. Chem. (1993) 268:22863–22873.
   Google Scholar
• TORPHY TJ, LIVI GP, CHRISTENSEN SB: Novel phosphodi-esterase inhibitors for the therapy of asthma. Drug News Perspect. (1993) 6:203–214.
   Google Scholar
• MURRAY KJ: Phosphodiesterase VA inhibitors. Drug **News Perspect. (1993) 6:150–156.
   Google Scholar
• LUGNIER C, SCHOEFF IFR P, LE BEC A, STROUTHOU E,STOCLET JC: Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. (1986) 35:1743–1751.
   PubMed Web of Science ®Google Scholar
• HIDAKA H, ENDO T: Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase-basic and po-tential clinical applications. Adv. Cycl. Nucleotide Protein Phosphorylation Res. (1984) 16:245–276.
   PubMedGoogle Scholar
• WE1SHAAR RE, KOBYLARZ-SINGER DC, KEISER J, HALEEN SJ: Subclasses of cyclic GMP-specific phosphodiesterase and their role in regulating the effects of atrial natri-uretic factor. Hypertension (1990) 15(5).528–540.
   PubMed Web of Science ®Google Scholar
• SAEKI T, SAITO I: Isolation of cyclic nucleotide phos- •phodiesterase isozymes from pig aorta. Biochem. Phar-macol. (1993) 46:833–839.
   PubMed Web of Science ®Google Scholar
• MIYAHARA M, ITO M, ITOH H et al.: Isoenzymes of cyclic ••nucleotide phosphodiesterase in the human aorta:characterization and the effects of E4021. Eur. J. Phar-macol. (1995) 284:25–33.
   PubMed Web of Science ®Google Scholar
• TORPHY TJ, CIESLINSKI LB: Characterization and selec-tive inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol. Phar-macol. (1989) 37:206–214.
   Web of Science ®Google Scholar
• SHAHID M, VAN AMSTERDAM RGM, DE BOER J et al.: Thepresence of five cyclic nudeotide phosphodiesterase isoenzyme activities in bovine tracheal smooth muscle and the functional effects of selective inhibitors. Br. J. Pharmacol. (1991) 104:471–477.
   Google Scholar
• ELLIOTT ICRF, BERRY JL, BATE AJ, FOSTER RW, SMALL RC:The isozyme selectivity of All 21-132 as an inhibitor of cyclic nucleotide phosphodiesterase activity. J. Enzyme Inhibit. (1991) 4:245–251.
   Google Scholar
• GIEMBYCZ MA, BARNES PJ: Selective inhibition of highaffinity type IV cyclic AMP phosphodiesterase in bovine trachealis by AM 21-132: relevance to the spasmolytic and anti-spasmogenic actions of AM 21-132 lathe intact tissue. Biochem. Pharmacol. (1991) 42:663–667.
   PubMed Web of Science ®Google Scholar
• SIMPSON AWM, REEVES ML, RINK TJ: Effects of SKRF94120, an inhibitor of cyclic nucleotide phosphodi-esterase Type M, on human platelets. Biochem. Pharma-col. (1988) 37:2315–2320.
   PubMedGoogle Scholar
• COQUIL JF, FRANKS DJ, WELLS JN, DUPUIS M, HAMET P:Characteristics of a new binding protein distinct from the kinase for guanosine 3',5'-monophosphate in rat platelets. Biochem. Biophys. Acta (1980) 631:148–165.
   PubMed Web of Science ®Google Scholar
• TANI T, SAKURAI K, KIMURA Y, ISHIKAWA T, HIDAKA H:Pharmacological manipulation of tissue cyclic AMP by Inhibitors: effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. In: Advances in Second Messenger and Phosphoprotein Re-search. Greengard P, Robison GA (Eds.), Raven Press, New York (1992) 25:215–227.
   PubMedGoogle Scholar
• NAGAKURA N, SAEKI T, HARADA K et al.: Mechanism ofSatigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol. Pbarm. Bull. (1996) 19:828–833.
   Google Scholar
• ITO M, NISHIKAWA M, FUJIOKA M et al.: Isoenzymes of ••cyclic nudeotide phosphodiesterase in human plate-lets: characterization and the effects of E4021. Cell. Signalling (1996). Submitted for publication.
   Google Scholar
• BERGSTRAND H, LUNDQUIST B : Partial purification and characterization of adenosine- and guanosine-3', 5'-mo-nophosphate phosphodiesterases from human lung tissue. Biochemistry (1976) 15: 1727-1734.
   Google Scholar
• BEAVO JA, HANSEN RS, HARRISON SA et al.: Identificationand properties of cyclic nucleotide phosphodiesterses. Mol. Cell Endocrinol. (1982) 28:387–410.
   PubMed Web of Science ®Google Scholar
• DE BOER J, PHILPOTT AJ, VAN AMSTERDAM RGM et al.:Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analy-sis using selective inhibitors. Br. J. Pharmacol, (1992) 106:1028–1034.
   Google Scholar
• TORPHY TJ, UNDEM BJ, CIESLINSKI LB et al.: Identifica-tion, characterization and functional role of phos-phodiesterase isozymes in human airway smooth muscle. J Pharmacol. Exp. 7ber. (1993) 265:1213–1223.
   Google Scholar
• BARGSTRAND F1, LUNDQUIST B, SCHURMANN A: Rat mast cell high affinity cyclic nucleotide phosphodiesterase: separation and inhibitory effects of two antiallergic agents. Mol. Pharmacol. (1978) 14:848–855.
   PubMed Web of Science ®Google Scholar
• BROUGHTON BJ, CHAPLEN P, KNOWLES P et al.: New Inhibitor of reagin-mediated anaphylaxis. Nature (1974) 251:650–652.
   PubMed Web of Science ®Google Scholar
• PRIGENT AF, FOUGIER S, NEMOZ G et al.: Comparison ofcyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta: separation and inhibition by selective reference phosphodiesterase inhibitors. Bio-chem. Pharmacol. (1988) 37:3671–3681.
   PubMed Web of Science ®Google Scholar
• MURRAY KJ, EDEN RJ, ENGLAND PJ et al: Potential use ofselective phosphodlesterase inhibitors lathe treatment of asthma. In: New Drugs for Asthma Therapy. Anderson GP, Chapman ID, Morley J (Eds.), Birkhanser Verlag, Basel (1991).27–46.
   Google Scholar
• •• •• •• •• •• SILVER PJ, DUNDORE RL, BODE DC et at: Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor. j Pharmacol. Exp. Ther. (1994) 271:1143–1149.
   PubMed Web of Science ®Google Scholar
• SildenafIL Ann. Drug Data Rep. (1995) 17:1019.
   Google Scholar
• DUMAITRE B, DODIC N: Synthesis and cyclic GMP phos- phodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones. J. Med. Chem. (1996) 39:1635–1644.
   PubMed Web of Science ®Google Scholar
• COSTE H, GRONDIN P: Characterization of a novel ••potent and specific inhibitor of type V phosphodi-esterase. Biochem. Pharmacol. (1995) 50:1577–1585.
   PubMed Web of Science ®Google Scholar
• WATKINS RW, DAVIS HR, FAWZI A et al.: Antihyperten- •sive, hemodynamic and vascular protective effects of SCH 51866, an inhibitor of cGMP hydrolysis. FASEB J. (1995) 9(3, Part 11). Abstract 1984.
   Google Scholar
• HAGIWARA M, ENDO T, ICANAYAMA T, HIDAKA H: Effect •of 1-(3-chloroanilino)-4-phenylphthalazine (MY5445), a specific inhibitor of cyclic phosphodiesterase, on human platelet aggregation. J. Pharmacol. Exp. Ther. (1984) 228:467–471.
   PubMed Web of Science ®Google Scholar
• SOUNESS JE, BRAZDIL R, DIOCEE BK, JORDAN R: Role of •selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vin-pocetine and 1-methy-3-isobuty1-8-(methylamino)xan-thine. Br. J. Pharmacol. (1989) 98:725–734.
   PubMed Web of Science ®Google Scholar
• TAKASE Y, SAEKI T, FUJIMOTO M, SAITO I: Cyclic GMP •phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 443,4-(methylenedioxy)ben-zyl)amino)-6,7,8-trimethoxy-quinazoline. J. Med. Chem. (1993) 36:3765–3770.
   Google Scholar
• TAKASE Y, SAEKI T, WATANABE N et al.: Cyclic GMP •phosphodiesterase inhibitors. 2. Requirement of 6-sub-stitution of quinazoline derivatives for potent and se-lective inhibitory activity. J. Med. Chem. (1994) 37:2106–2111.
   Google Scholar
• SAEKI T, ADACHI H, TAKASE Y et al.: A selective type V ••phosphodiesterase inhibitor, E4021, dilates porcinelarge coronary artery. J. Pharmacol. Exp. Ther. (1995) 272:825–831.
   PubMed Web of Science ®Google Scholar
• KONDO K, SUGITANI M, KONISHI Y, KITAKAZE M: Poten- •tial for combined PDE-V/TICA2 synthase inhibitors. In: Phosphodiesterase Inhibitors and their Therapeutic Potential Abstract Book. William Harvey Research Conferences (1995):11.
   Google Scholar
• NOMOTO Y, TAKAI H, OHNO T et al.: Studies of cardio- •tonic agents. 8. Synthesis and biological activities of optically active 6-(4-(benzylamino)-7-quinazoliny1)-4,5-dihydro-5-methy1-3(2H)-pyridazinone (1015232). J. Med. Chem. (1996) 39:297–303.
   Google Scholar
• SCHOEI-1.1ER P, LUGNIER C, DEMESY-WAELDELE F, STO- •CLET JC: Role of cyclic AMP- and cyclic GMP-phosphodi-esterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta: a study with selective inhibitors. Biochem. Pharmacol. (1987) 36(22):3965–3972.
   Google Scholar
• HARRIS AL, LEMP BM, BENTLEY RG et al.: Phosphodi-esterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J. Pharmacol. Exp. Ther (1989) 249(2):394–400.
   PubMed Web of Science ®Google Scholar
• MARTIN W, FURCHGOTT RE, VILLANI GM, JOTHIANAN-DAN D: Phosphodiesterase inhibitors induce endothe-lium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released en-dothelium-derived relaxing factor. J. Pharmacol. Ther. (1986) 237(2):539–547.
   PubMed Web of Science ®Google Scholar
• MERKEL LA, RIVERA LM, PERRONE MH, LAPPE RW: In vitro •and in vivo interactions of nitrovasodilators and zapri-nast, a cGMP-selective phosphodiesterase inhibitor. Eur. J. Pharmacol. (1992) 216:29–35.
   PubMed Web of Science ®Google Scholar
• DELPY E, GOUVILLE AM: Cardiovascular effects of a ••novel, potent and selective phosphodiesterase 5 inhibi-tor, DMPPO: in vitro and in vivo characterization. Br. J. Pharmacol. (1996) 118:1377–1384.
   PubMed Web of Science ®Google Scholar
• WEISHAAR RE, KOBYLARZ-SINGER DC, KEISER J et al.: Subclasses of cyclic GMP-specific phosphodiesterase and their role in regulating the effects of atrial natri-uretic factor. Hypertension (1990) 15;528–540.
   PubMed Web of Science ®Google Scholar
• AHLNER J, ANDERSSON RGG, AXELSSON KL, BUNNFORS I, WALLENTIN L: Effects of dipyridamole on the glyceryl-trinitrate-induced inhibition of coronary artery muscle tone and platelet aggregation in relationship to cyclic GMP metabolism. Arch. Pharrnacol. Toxicol. (1985) 57:88–95.
   PubMedGoogle Scholar
• MERKEL L: Zaprinast a cGMP-selective phosphodi-esterase inhibitor. Cardiovasc . Drug Rev. (1993) 11(4)501–515.
   Google Scholar
• MCMAHON EG, PALOMO MA, MEHTA P, OLINS GM: Dc- ▪pressor and natriuretic effects of M&B 22,948, a guanos-ine cyclic 3',5'-monophosphate-selective phospho-diesterase inhibitor. J. Pharmacol. Exp. Ther. (1989) 251(3):1000–1005.
   PubMed Web of Science ®Google Scholar
• DUNDORE RL, HABEEB PG, PRATT PF et al.: Differential hemodynamic responses to selective inhibitors of cy-clic nucleotide phosphodiesterases in conscious rats. J. Cardiovasc. Pharmacol. (1992) 19:937–944.
   PubMed Web of Science ®Google Scholar
• DUNDORE RL, PRATT PF, O'CONNOR B, BUCHHOLZ RA, •PAGANI ED: Nm-Nitro-L-arginine attenuates the accumu-lation of aortic cyclic GMP and the hypotension pro-duced by zaprinast. Eur. J. Pharmacol. (1991) 200:83–87.
   PubMed Web of Science ®Google Scholar
• NISHINO M, ADACHI H, ISHIHARA H et al.: Hypotensive •effects of a novel phosphodiesterase V inhibitor, E4021, In rats. Jpn.J. Pharmacol. (1995) 67(Suppl. I):P3–95.
   Google Scholar
• ADACHI H, SAEKI T, MORI N, SAITO I: Haemodynamics •effects of E4021, a novel selective and potent cGMP-phosphodiesterase inhibitor, in pigs. Jpn. Circ. (1994) 58\(Suppl. 0:0130.
   Google Scholar
• CLARICE WR, IJEZONO S, CHAMBERS A, DOEPFNER P: The •Type III phosphodiesterase inhibitor milrinone and Type V PDE inhibitor dipyridamole individually and synergistically reduced elevated pulmonary vascular resistance. Pulmonary Pharmacol. (1994) 7:81–89.
   PubMedGoogle Scholar
• SKIMMING JW, DEMARCO VG, KADOWITZ PJ, CASSIN S: •Effects of zaprinast and dissolved nitric oxide on the pulmonary circulation of foetal sheep. Pediatr. Res. (1996) 39(2):223–228.
   PubMed Web of Science ®Google Scholar
• BRANER DA, FINEMAN JR, CHANG R, SOIFER SJ: M&B •22948, a cGMP phosphodlesterase inhibitor, is a pulmo-nary vasodilator in lambs. Am.J. Physiol. (1993) 264:H252–H258.
   PubMed Web of Science ®Google Scholar
• KODAMA K, ADACHI H, YOSITAKE S, SAITO I: Ameliora- •dye effects of a novel phosphodiesterase V inhibitor, 42. •• Oa E4021, in canines with pulmonary hypertension. Jpn. Pharmacol. (1995) 67\(Suppl. 0:P3–96.
   Google Scholar
• COHEN All, HANSON K, MORRIS K et al.: Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phos-phodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest. (1996) 97:172–179.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, KANDA T, INOUE M et al.: A selective Type •V phosphodiesterase inhibitor, E4021, protects the de-velopment of right ventricular hypertrophy and medial thickening of pulmonary arteries in rat model of pul-monary hypertension. Life Sci. (1996).
   Google Scholar
• Submitted for pub-lication. KODAMA K, ADACHI H, MORI N, SAITO I: Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischaemia in guinea pigs. Eur. J. Pharmacol. (1994) 263:93–99.
   PubMed Web of Science ®Google Scholar
• SZILVASSY Z, JAKAB I, FERDINANDY P et at.: Zaprinast, cicletanine, and verapamil attenuate overdrive pacing-induced myocardial ischaemia in conscious rabbits. Life Sci. (1993) 53(1):PL13–PL18.
   Google Scholar
• SILVER PJ, PAGANI ED, GARAVILLA L et al.: Reversal of •nitroglycerin tolerance by the cGMP phosphodi-esterase inhibitor zaprinast. Eur. I Pharmacol. (1991) 199:141–142.
   PubMed Web of Science ®Google Scholar
• DUNDORE RE, PRATT PF, HALLENBECK WI) et at.: Sodium nitroprusside potentiates the depressor response to the phosphodiesterase inhibitor zaprinast in rats. Eur. Pharmacol. (1990) 185:91–97.
   Google Scholar
• WINSLOW R : Pfizer explores treatment for impotence •- trial pill offers promise of restoring men's sexual function. The Wall Street J. (May 6, 1996):B8.
   Google Scholar
• ADACHI H, YOSHITAKE S, SAITO I: Effects of a novel •phosphodiesterase V inhibitor, E4021, on cardio-haemodynamics and plasma hormones in pigs with heart failure. Jpn.Ji Pharmacol (1995) 67:P3–138.
   Google Scholar
• MAEDA Y, TSL'TAMOTO T, WADA A et al.: Effect of E4021, •a novel selective phosphodiesterase type V inhibitor, on congestive heart failure. Jpn. Circ. J. (1996) 60\(Suppl. 0:0979.
   Google Scholar
• ANDERSSON TLG, VINGE E: Interactions between iso- prenaline, sodium nitroprusside, and isozyme-selec-tive phosphodiesterase inhibitors on ADP-induced aggregation and cyclic nucleotide levels in human platelets. J. Cardiovasc. Pharmacol. (1991) 18:237–242.
   PubMed Web of Science ®Google Scholar
• MEANWELL NA, SEILER SM: Inhibition of platelet cAMP phosphodiesterase. Drugs of the Future (1990) 15:369–390
   Google Scholar
• HASLAM RJ, SALAM SE, FOX JEB, LYNHAM JA, DAVIDSON MML: Role of cyclic nucleotides and of protein phospho-rylation in the regulation of platelet function. In: Cellu-lar Response Mechanism and their Biological Significance. Rotrnan A, Meyer FA, Gilter C, Silberberg A (Eds.), John Wiley & Sorts Ltd., (1980):213–231.
   Google Scholar
• RADMSKI MW, PALMER RMJ, MONCADA S: The anti-aggre- gating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br.]. Pharmacol. (1987) 92:639–646.
   PubMed Web of Science ®Google Scholar
• CATERINA RF, GIANNESSI D, BERNINI W, MAZZONE A: Organic nitrates: direct antiplatelet effects and syner-gism with prostacyciln-antiplatelet effects of organic nitrates. Thromb. Haemost. (1988) 59:207–211.
   PubMed Web of Science ®Google Scholar
• MAURICE DH, HASLAM RJ: Molecular basis of the syner-gistic inhibition of platelet function by nitrovasodila-tors and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Phannacol. (1990) 37:671–681.
   PubMed Web of Science ®Google Scholar
• POHL U, BUSSE R: EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed. Circ. Res, (1989) 65:1798–1803.
   PubMed Web of Science ®Google Scholar
• RADOMSKI MW, PALMER RMJ, MONCADA S: The role of •nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Comm. (1987) 148:1482–1489.
   PubMed Web of Science ®Google Scholar
• SNEDDON JM, VANE JR: Endothelium-derived relaxing •factor reduces platelet adhesion to bovine endothelial cells. Proc. Natl. Acad. Sci. USA (1988) 85:2800–2804.
   PubMed Web of Science ®Google Scholar
• VENTURINI CM, WESTON LK, KAPLAN JE: Platelet cGMP, •but not cAMP, inhibits thrombin-induced platelet adhe-sion to pulmonary vascular endothelium. Am.]. Physiol. (1992) 263:H606–H612.
   PubMed Web of Science ®Google Scholar
• GROVES PH, LEWIS NU, CHEADLE HA, PENNY WJ: SIN-1 ••reduces platelet adhesion and platelet thrombus forma- tion in a porcine model of balloon angioplasty. Circu-lation (1993) 87:590–597.
   PubMed Web of Science ®Google Scholar
• TRAPANI AJ, SMITS GJ, MCGRAW DE, MCMAHON EG, BLAINE EH: Hemodynamic basis for the depressor ac-tivity of zaprinast, a selective cyclic GMP phosphodi-esterase inhibitor. J. Pharmacol. Exp. Ther. (1991) 258:269–274.
   PubMed Web of Science ®Google Scholar
• LEE KC, CANNIFF PC, HAMEL DW: Comparative •haemodynamics and renal effects of low KM cGMP phosphodiesterase inhibitors cicletanine and zaprinast In anesthetized dogs. Drug Dee. Res. (1991) 23:127–144.
   Web of Science ®Google Scholar
• WILKINS MR, SETTLE SL, STOCKMANN PT, NEEDLEMAN P: •Maximizing the natriuretic effect of endogenous atriopeptin in rat model of heart failure. Proc . Natl. Acad. Sci. USA (1990) 87:6465–6469.
   PubMed Web of Science ®Google Scholar